K.d. Pharma Bexbach Gmbh

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Frankgen Biotechnologie Ag

Thomas Floss

Wolfgang Wurst

Frank Schnütgen

Marcus Otto Walter Grimm

Harald Von Melchner

Tobias Hartmann

Anke Wittmann

Patricia Ruiz

Silke De-Zolt

Jens Hansen

An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.

Omega-3 and/or omega-6 fatty acid(s) in impaired sphingolipid metabolism

Growing community of inventors

Munich, Germany

Thomas Floss